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Background: HIV testing rates in many hyper-endemic areas are lower than needed to curtail the HIV epi-
demic. New HIV testing strategies are needed to overcome barriers to traditional clinic based testing; HIV
self-testing is one modality that offers promise in reaching individuals who experience barriers to clinic-
based testing.
Methods: We conducted a randomized control trial among young women ages 18-26 living in rural Mpuma-
langa, South Africa where they were randomized in a 1:1 allocation to either the: (1) HIV Counseling and
Testing (HCT) arm: an invitation to test at one of the 9 local government clinics where free HCT is provided
and is standard of care (SOC), or (2) choice arm: choice of either a clinic-based HCT invitation or oral HIV
Self-Testing (HIVST) kits. Depending on the arm, participants were also provided either: (1) 4 HCT invitations
to provide to peers/partners for HIV testing at one of the 9 local clinics, or (2) 4 HIV self-test kits to provide to
peers/partners (thus 5 total HIVST kits or HCT invitations). Young women were asked to return 3 months and
9 months after enrollment to assess testing uptake and invitation or kit distribution to peers and partners
and experiences with testing. Peers and partners who were reported by index participants to have received
kits/invitations during follow-up visits were also invited to attend a study visit to assess their testing experi-
ences. The trial is registered at clinical trials.gov NCT03162965.
Findings: 287 young women were enrolled and randomized, with 146 randomized to the HCT arm and 141 to
the choice (HCT or HIVST) arm. Of those randomized to the choice arm, over 95% (n=135) chose the HIV self-
testing kit and only 6 individuals chose HCT. At the 3-month follow-up visit, 92% of index participants in the
choice arm reported having tested for HIV compared to 43% of participants in the HCT arm, resulting in a sig-
nificant risk difference of 49% (95% CI 40%, 58%). By 9 months, this difference decreased to a risk difference of
25% (95% CI 17%, 33%) between arms (96% in the choice arm and 72% in the HCT arm). Participants in the
choice arm were also more likely to invite peers and partners to test compared to the HCT arm (94% vs. 76%
or an average of 4.97 vs 2.79 tests). Few male partners were invited to test by index participants; however,
index participants in the choice arm were more likely to have their male partners test than index participants
in the HCT arm (RR 2.99, 95% CI 1.45, 6.16).
Interpretation: When given a choice between clinic-based HIV testing and HIV oral self-testing, the over-
whelming majority of young women chose HIVST. In addition, those offered a choice of HIV testing modality
were much more likely to test, distribute test kits to peers and partners, and to have peers and partners who
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Other strategies to reach men with testing are needed.
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Evidence before this study
HIV self-testing (HIVST) offers individuals the opportunity to
test on their own terms, reducing many barriers to clinic based
HIV testing including wait times, privacy concerns and costs
associated with clinic attendance. The evidence on self-testing
to date has shown that offering HIVST can increase HIV testing,
with the bulk of the data coming from Men who have sex with
Men (MSM), sex workers or pregnant women. To date, there is
no data from a randomized trial showing that offering HIVST to
young women (who are not pregnant, recruited from antenatal
care centers, or sex workers) can increase testing in this high
priority population and there is also a lack of evidence as to
whether young women would distribute test kits to friends and
partners.
Added value of this study
This study is the first RCT among young women who are not
pregnant or engaged in sex work to examine the impact of
offering a choice of HIVST to young women on their testing
uptake and on testing uptake among friends and partners as
compared to standard, provider delivered HIV Counseling and
Testing (HCT). We found that the vast majority (95%) of young
women chose HIVST over clinic based HCT and that HIVST
resulted in a difference in testing uptake between groups of
49% at the 3 month follow up visit (95% CI 40%, 58%). We also
found that young women offered HIVST were more likely than
those offered HCT invitations to have friends and partners test.
By the 9-month visit, 84% of young women in the choice/HIVST
arm had at least one peer or partner who reported testing com-
pared to 44% in the HCT arm for a risk difference of 41% (95% CI
30%, 51%). There were no social harms reported in this study
and overall feasibility of conducting HIVST was high.
Implications of all the available evidence
Increasing evidence from different populations and contexts
has found that offering HIVST to individuals results in a large
and significant increase in HIV testing and that secondary dis-
tribution of HIVST to friends and partners can increase testing
among an even larger network of individuals. There is minimal
evidence that HIVST distribution leads to social harms and in
many high prevalence HIV settings, where governments are
actively trying to de-congest clinics, HIVST can reduce clinic
burden and help reach the first 90 in the UNAIDS testing target;
there is a need though for alternative approaches to reach men
other than through their female partners.1. Introduction
South Africa has the most Adolescent Girls and Young Women
(AGYW) ages 15- 24 years living with HIV in the world. An estimated
6% of South African AGYW ages 15-19 are HIV infected, increasing toover 17% by age 20-24; incidence rates exceed 3% in many sub-
groups [1,2]. Despite this, HIV testing and linkage to care remains
inadequate in this population; fewer than 50% of all 15-19 year olds
reported ever testing in 2016 [3], only 14% of HIV-positive adoles-
cents are on antiretroviral therapy (ART), and just 10% are virally sup-
pressed [1,4]. In addition, young men ages 18-35 the partners of
many of these young women are some of the least likely to test for
HIV [3]. Novel strategies to get young people to test for HIV are
needed.
A substantial proportion of new infections are spread by persons
unaware of their HIV status, making it urgent that we improve testing
uptake and reduce the number of undiagnosed cases of HIV [5,6].
Ensuring universal access to HIV prevention, treatment and care in
countries with generalized epidemics, such as South Africa, will
require near-complete uptake of annual HIV testing by all adults,
which could be achieved by expanding delivery options to overcome
some of the obstacles to provider-delivered HIV Counseling and Test-
ing (HCT). In light of recent scale-up of HCT in many high prevalence
settings not reaching key populations at risk for HIV infection, new
strategies are needed to identify hard-to-reach, undiagnosed cases of
HIV infection.
HIV self-testing (HIVST) has the potential to increase the propor-
tion of people ever tested, increase testing frequency, and encourage
earlier detection of HIV and thus earlier treatment [7,8]. With self-
testing, individuals collect their own sample and perform a simple,
rapid HIV antibody test in the absence of a provider. As a result,
HIVST can address some of the structural barriers to testing, such as
privacy concerns, lack of access to care (e.g. lack of transportation),
stigma, and clinic wait times [9,10] Self-testing has the potential to
reach those who have traditionally been reluctant or unable to attend
clinics and has been found to be acceptable and feasible in a number
of sub-Saharan African countries among a range of populations
[8,11,12,13]. A recent meta-analysis of 5 randomized control trials
found HIVST to increase uptake and frequency of HIV testing [7].
Many of the studies among women have focused on pregnant or
post-partum women and female sex workers, finding that women
have been successful in giving HIV test kits to partners [14-17]. Sec-
ondary distribution of HIV self-test kits is one way to reach popula-
tions who test less frequently and hard-to-reach groups like
adolescents, men and key populations.
2. Methods
2.1. Study design
This was a 1:1 individually randomized controlled trial aiming to
determine whether providing young women with a choice of testing
strategies as compared to traditional HCT would result in greater
uptake of testing among young women and their peers and partners.
Young women ages 18-26 were randomized to either the: 1) HCT
arm: an invitation to a local clinic for free HCT (standard of care) or,
2) HCT/HIVST choice arm: choice of either free HCT or oral HIVST kits.
Young women choosing HIVST in the choice arm were provided with
5 HIVST kits (OraQuick); young women randomized to or choosing
HCT were given 5 invitations to test for free at local government clin-
ics. In both arms, one kit or invitation was intended for the trial
(index) participant, while the remaining four were intended for dis-
tribution to peers and partners. Young women were asked to return
3 months and 9 months after enrollment to assess testing uptake and
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testing modality. Peers and partners that young women reported giv-
ing kits/invitations to at each follow-up visit were also contacted and
invited to attend a study visit where they were interviewed about
their experiences with the testing modality they were provided with.
The study was conducted in the rural Bushbuckridge sub-district
of Mpumalanga Province, South Africa in the Medical Research Coun-
cil / Wits University Rural Public Health and Health Transitions
Research Unit’s field center. This area is characterized by high unem-
ployment and temporary migration for work, high uptake of social
grants, poor provision of water and sanitation, and high levels of HIV
infection in the adult population.
2.2. Ethics
This study was approved by the Institutional Review Boards at the
University of North Carolina-Chapel Hill and the University of Califor-
nia-San Francisco, the Human Research Ethics Committee (Medical)
at the University of the Witwatersrand in South Africa, and the Mpu-
malanga Department of Health and Social Development Research
Committee. The protocol was registered at clinical trials.gov ID num-
ber - NCT03162965.
2.3. Participants
Young women were recruited from the Agincourt Health and
socio-Demographic Surveillance System (AHDSS) sampling frame.
This is an annual household census of over 120,000 individuals living
in 31 villages in the study area (www.agincourt.co.za). A sample was
drawn from the AHDSS based on age and not having previously par-
ticipated in studies with regular HIV testing. Households were visited
for each young woman to determine eligibility and willingness to
participate in the study. Inclusion criteria included: between the ages
of 18-26; not having participated in HPTN 068, an RCT with annual
HIV testing; reported having had sex in the past 3 months and plan-
ning to have sex again in the next three months; planning to stay in
the Agincourt HDSS area for the next nine months; able and willing
to provide informed consent; willing to comply with study proce-
dures, and did not self report HIV-positive serostatus.
Peers and partners invited by the young women had to be 18 years
old and above to participate in the study. Recruited peers and part-
ners recruited by index participants were not entered into the index
participant pool. All primary analyses are based on the original ran-
domized index participants only.
Written informed consent either in English or Shangaan (the local
language) was obtained from all participants.
2.4. Randomization
Young women ages 18-26 were randomized using block randomi-
zation with a 1:1 allocation to either the HCT arm or the choice arm.
Randomization sequences were generated by the data team in the US
and sent to South Africa. The random allocation was printed in 440
sealed opaque envelopes ordered 1-440 in South Africa. In every
block of 4 there were 2 choice and 2 HCT allocations in random order.
Participants randomly selected an envelope from a box with a set
number of blocks of envelopes put into the box and opened it to
reveal the study arm in the presence of a research team member. The
study was not blinded.
2.5. Procedures
Following consent young women were asked to complete a base-
line questionnaire and then randomized into the study arms. The
questionnaire was interviewer administered and included questions
about demographics, history of testing for HIV, and sexual behavior.A finger prick blood sample was collected from all participants onto a
dried blood spot (DBS) card for storage, so that at the end of the trial,
ie at the 9-month visit, incident cases could be distinguished from
those who were already HIV positive at baseline. Young women were
followed up 3 and 9 months after baseline to determine their experi-
ences with testing.
Young women who were randomized to the choice arm and chose
self-testing were provided with five self-test kits for themselves,
their peers and their partner(s). Each test kit was numbered and
linked to the index participant using a unique identifier. Participants
who chose the HIVST were given the OraQuick InHome Rapid HIV- 1/
2 Antibody TestTM (Orasure Technologies) which is FDA approved
and WHO pre-qualified and approved for use in South Africa. Young
women were provided with a demonstration of how to use the kit,
shown an online video created by the manufacturer demonstrating
use in the local language (which could be shown to peer/parnters on
a smartphone), and given an opportunity to ask any questions about
the kit. Test kits included the instructions for use provided by the
manufacturer in the local language (Tsonga); these instructions
include pre- and post-test counseling information and a “frequently
asked questions” document on HIV self-testing. The study team pro-
vided a list of local HIV/AIDS and related resources. The study also
provided a self-testing log to document use of the self-test to be
returned to the study team. The log included date and time of test,
people present during testing, and test results (with graphics display-
ing possible results participants were to select the image that best
represented the test result). It was emphasized that as the test is an
antibody-based test, it was important to both test again in 3 months
if HIV negative and to get confirmatory testing at the clinic after test-
ing HIV positive.
Young women who were randomized to clinic-based HCT and
those who chose clinic-based HCT in the choice arm were provided
with an invitation to test at one of the 9 local government primary
care clinics in the AHDSS study area where rapid HIV testing is pro-
vided free of charge. They were also given linked HCT invitation cards
for 4 peers and sex partners to test; in total there were 5 HIVST kits or
5 HCT invitations given to young women. Cards were linked to the
index partner using a confidential unique identifying number in
order to determine if peers and sex partners of index cases returned
to the clinic for testing.
Young women in both arms were advised to provide the test kits/
invitations to test to peers and sex partners within 1 month of receiv-
ing the kit and advised to tell sex partners and peers to use the self-
test kit or go to the clinic within 3 months of receiving it. It was
emphasized that participants should think carefully about who it
would be appropriate to share the HIV testing kits/invitations with
and remind them that they should only provide them to sex partners
and peers with whom they felt safe giving HIV test kits/invitations to.
At the 3- and 9-month follow-up visits an assessment for all index
participants was undertaken. The assessment included questions
about their testing experiences, depression, intimate partner vio-
lence, HIV knowledge and any negative or positive experiences as a
result of the study. Additionally, they were asked to provide names
and contact information for the peers and partners to whom they
gave test kits/invitations. All peers and sex partners for whom the
participant provided contact information at the 3 or 9 month visit
were invited to attend a study visit. Those that were interested were
asked to visit the study offices, provide written informed consent and
take part in a questionnaire (similar to the survey conducted with
the index young women).
At the 3-month follow-up assessment, young women who tested
negative were offered the opportunity to receive more HIVST kits or
more HCT invitation cards (the same number as at baseline, 5 in
total). Those that tested positive were offered more kits to distribute
to their peers and partners. Young women who were randomized to
the “choice” arm had the option to change their testing choice. That
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month 3 and vice versa.
At the 9-month follow-up visit, young woman who self-reported
as HIV negative or status unknown completed an in-office HIV self-
test on her own (both study arms), while observed by a study coun-
selor. Participants were given the instruction sheet on how to use the
test kit but were not shown how to use it. All index participants also
had a dried blood spot (DBS) card collected for confirmatory HIV test-
ing at the 9-month visit. Cards were stored in -80C freezers on site
and shipped to the laboratory following cold-chain procedures.
Everyone who tested HIV positive during the study was encour-
aged to link to care by study interviewers. All individuals who
reported testing HIV positive at either the 3-month or 9-month visit
were asked whether or not they sought care for their HIV diagnosis,
and reminded about the importance of starting treatment. We con-
ducted care calls 4 weeks prior to the 3-month and 9-month visits at
which we reminded the participant to invite peers and partners to
their testing modality and to use the testing modality if they have not
yet used it. If they reported testing HIV-positive at the time of the
care call they were encouraged to link to care for confirmatory testing
if they have not yet done so.
2.6. Statistical Analysis
The primary outcome of the trial was uptake of HIV testing by
study arm at the 3-month visit, measured by the proportion of index
participants self-reporting HIV testing in the choice arm (either HCT
or HIVST) compared to those in the HCT arm. The secondary outcome
of the trial is the proportion of peers and sex partners reporting hav-
ing tested for HIV in the choice arm compared to those in HCT arm at
3 months. We also assessed the proportion reporting testing by study
arm at the 9-month visit for both index participants and their peers
and partners.
2.6.1. Sample size
An original sample size of 200 index participants per arm (400
total) was estimated for the main study aims assuming a 20% differ-
ence in the take-up of HIV testing between study arms. However,
early study results in July 2017 with 272 participants recruited at
that time found that the difference in uptake between arms to be
greater than four times initial estimates, suggesting that the study
would be overpowered to detect differences for the main study aims.
The study team simulated the estimated impact of early recruitment
cutoff on statistical power using a range of plausible scenarios. The
simulation approach is analogous to an empirical power calculation,
but better utilizes existing data and expected statistical methods to
generate more realistic power estimates [18]. It was determined that
detection of the main study aims was more than adequate at current
recruitment levels. As a result, the decision was made to cease addi-
tional recruitment, resulting in a total enrollment of 287 participants.
The study adhered to Consort guideline criteria.
2.6.2. Statistical methods
All main analyses are performed as intent to treat analyses
between the two trial arms. Risk and count differences and their
respective 95% confidence intervals are estimated by ordinary least
squares (OLS) regression  or the untransformed case of generalized
linear modelswith adjustment to standard errors for heteroskedas-
ticity. For binary outcome variables, risk ratios were also calculated
and provided, using the standard 2£ 2 method. For the index partici-
pant analyses, HC2 estimators were used for confidence intervals
(CIs) for the OLS estimates for heteroskedasticity robustness [19], and
the Wald estimator for the risk ratios. Differences between the peers
and partners recruited from index participants were also assessed
using OLS and risk ratios, with adjusted confidence intervals to
account for clustering. CIs were estimated with the CR2 estimator forall OLS estimates [19], and with a cluster-bootstrap estimator for the
relative risks. No additional control variables were included for any
regression or analysis beyond the binary indicator for the assigned
arm of the index participant and an intercept term.
All 9-month statistics are cumulative from baseline, inferring HIV
status and testing events from both baseline to 3-month and 3-
month to 9-month, to estimate the number of testing events and
sero-conversions from baseline. Unless otherwise noted, missing
data for any reason, including not attending a visit or refusal to
answer a question, are treated as the event or status not detected and
count as a 0. This is performed for consistency across 3-month and 9-
month measurements.
All calculations were performed in R v3.6.1 [20], with risk ratios
calculated with the epitools package v0.5-10 [21] and OLS-based esti-
mators and their confidence intervals in the estimatr package v0.20.0
[22].
2.6.3. Treatment of peers and partners
Peers and partners were each associated with an index partici-
pant. In some instances, the same peer/partner could have been
invited to test (HCT or Choice arm) by more than one index partici-
pant. Each occurrence of a peer or partner invitation is counted sepa-
rately for each index participant with whom they are associated, and
as such the same peer/partner may be counted more than once in the
total number of testing invitations or test kits distributed by index
cases. However, peers/partners who were invited into the study by
more than one index and ultimately entered the study (e.g. signed
informed consent and completed a questionnaire) were only allowed
to enroll in the study once and complete one questionnaire pertain-
ing to the first index case who invited them, this occurred for
26 peer/partners.
2.7. Role of the funding source
The funder of the study had no role in study design, data collec-
tion, data analysis, data interpretation, or writing of the report. The
corresponding author had full access to all the data in the study and
had final responsibility for the decision to submit for publication.
3. Results
3.1. Findings with index participants
Of 1317 young women contacted and screened for eligibility, 968
(73%) were not eligible: 382 were no longer living in the study area,
216 were not sexually active, 192 had been in a prior trial that offered
annual HIV testing, and 103 were not planning to stay in the study
area for the study duration (Fig. 1). Other reasons for ineligibility
included: not willing to distribute test kits (n=46), self report being
HIV positive (n=34), no one home or refused assessment of eligibility
(n=37). We could not assess eligibility of 10 participants. The remain-
ing 339 young women were eligible to participate. Of these, 52 (15%)
refused to participate (Fig. 1).
Overall, 287 young women were enrolled between December
2016 and July 2017, with 146 randomized to the HCT arm and 141 to
the choice arm. Of those randomized to the choice arm, over 95%
(n=135) chose to use the HIV self-test kit (HIVST) and only 6 individu-
als chose HCT.
At baseline, the mean age of index participants in both arms was
21 years, having completed 12 years of schooling on average. The
mean number of life time partners was 2.7 vs 2.9 (HCT vs. choice,
respectively) and 67% reported having been pregnant before (Table 1).
Prior to the study, 94% (265/283) of participants in both arms
reported ever having tested for HIV and 76% (n=135, HCT) and 77%
(n=130, choice) reported having tested for HIV in the last 12 months.
The majority (84%, n=223/265) reported having tested at a
Fig. 1. CONSORT Diagram: Index participants.
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of participants (n=225/283) also reported feeling very comfortable
asking their primary partner to test for HIV, while only 43% (n=122/
283) reported being very comfortable asking a non-primary partner
to test for HIV.
Follow up visits occurred between March 2017 and May 2018. At
the 3-month follow-up visit, 92% of index participants in the choice
arm reported having tested for HIV compared to 43% of participants
in the HCT arm resulting in a risk difference of 49% (95% CI 0.40,0.58)
(Table 2). At the 9-month visit, 96% of participants in the choice arm
reported having tested for HIV compared to 72% of HCT armparticipants, resulting in a 25% difference in risk between arms (95%
CI 0.16, 0.33) (Table 2).
Index participants reported giving HIVST kits or HCT invitations to
570 peers and partners between baseline and the 3-month visit; 373
in the choice arm and 198 in the HCT arm. 87% of index participants
gave at least one test to a peer or partner compared to 60% in the HCT
arm, resulting in a 27% risk difference (RR 1.45 95% CI 1.25,1.68)
(Table 2). More choice arm participants reported giving a test kit/
invitation to at least one male partner than HCT participants at both
3-month (18% in choice vs. 6% in HCT; RR 2.99, 95% CI 1.45, 6.16) and







Descriptive statistics mean (SD) mean (SD)
Age 21.1 (2.2) 20.7 (2.1)
Years of school 12.2 (0.7) 12.2 (0.9)
Age at first sex 16.9 (1.6) 16.7 (1.7)
Number of sex partners ever 2.7 (1.5) 2.9 (1.8)
Number of sex partners in the last 12 months 1.09 (0.31) 1.17 (0.41)
Received pay for work 0.15 (0.35) 0.10 (0.30)
Previously used an HIV self-test 0.02 (0.14) 0.04 (0.20)
Has ever tested for HIV before trial 0.94 (0.24) 0.94 (0.25)
Has tested for HIV in last 12 months 0.76 (0.43) 0.77 (0.42)
Ever been pregnant 0.66 (0.47) 0.68 (0.47)
Arm assignment n (%) n (%)
Assigned or chose HCT protocol 146 (100%) 6 (4.3%)
Assigned or chose self-test protocol 0 (0%) 135 (96.7%)
Table 2
Main outcome results for index participants.
HCT (n=146) Choice
Panel a: Binary outcome variables
at Month 3
Proportion of outcom
Used at least one test 0.43 0.92
Used test and at least one was
HIV positive
0.02 0.04
Gave at least one test away 0.57 0.87
Gave at least one test to a
partner
0.06 0.18
At least one peer/partner linked
to trial*
0.45 0.78
At least one peer/partner used at
least one test*
0.31 0.76
At least one peer/partner tested
positive*
0.03 0.06
Became pregnant since baseline 0.07 0.02
Panel b: Count outcome variables at Month 3
Number of tests used
Number of tests given away
Number of tests given to partner(s)
Number of peers/partners linked to trial*
Number of peer/partners who received at least one test
Number of peer/partners who used at least one test*
HCT (n=1
Panel c: Binary outcome variables at Month 9 Proporti
Used at least one test 0.72
Used test and at least one was HIV positive 0.03
Gave at least one test away 0.76
Gave at least one test to a partner 0.08
At least one peer/partner linked to trial* 0.60
At least one peer/partner used at least one test* 0.44
At least one peer/partner tested positive* 0.04
Became pregnant since baseline 0.14
Panel d: Count outcome variables at Month 9
Number of tests used
Number of tests given away
Number of tests given to partner(s)
Number of peers/partners linked to trial*
Number of peer/partners who received at least one test
Number of peer/partners who used at least one test*
Unless otherwise noted, all data are self-reported from t
linked with index participant.
6 A. Pettifor et al. / EClinicalMedicine 21 (2020) 100327No harms were reported by index participants in the 3 or 9 month
survey. One participant in the HCT arm reported as a harm that she
was turned away from a clinic when presenting with her study invi-
vation to access HCT, however she did not report this in the survey.
One social harm was reported to the IRB for an individual recruited
to participate in the study (but did not enroll in the study) because a
boyfriend was upset about study staff contacting her to take part.3.1.1. Findings from peers and partners
Of the 1107 peers and partners reported by the index cases by the
end of the trial, 609 (55%) attended a visit and enrolled in the study,
193 in the HCT arm and 416 in the choice arm (Fig. 2). The majority
of peer/partners were female (Table 3) in both arms, although a
higher proportion of those invited in the choice arm were male (26%)
than those invited from the HCT arm (19%) (RR 1.38, 95% CI:
1.03,1.90).arm (n=141)
e Risk difference Risk ratio
0.49 [0.40,0.58] 2.14 [1.76,2.59]
0.01 [-0.02,0.05] 1.73 [0.42,7.09]
0.30 [0.21,0.40] 1.53 [1.31,1.79]
0.12 [0.05,0.20] 2.99 [1.45,6.16]
0.33 [0.23,0.44] 1.75 [1.43,2.14]
0.45 [0.35,0.55] 2.46 [1.90,3.19]
0.03 [-0.02,0.08] 1.86 [0.64,5.43]
-0.05 [-0.09,0.00] 0.31 [0.09,1.11]
HCT (n=146) Choice arm (n=141)
Mean count of outcome Count difference
0.43 0.96 0.53 [0.43,0.62]
1.36 2.65 1.29 [1.00,1.62]
0.06 0.20 0.14 [0.05,0.22]
0.74 1.69 0.95 [0.70,1.21]
* 0.74 1.65 0.91 [0.70,1.17]
0.43 1.60 1.16 [0.90,1.40]
46) Choice arm (n=141)
on of outcome Risk difference Risk ratio
0.96 0.25 [0.17,0.33] 1.34 [1.21,1.49]
0.05 0.02 [-0.03,0.06] 1.45 [0.47,4.46]
0.94 0.18 [0.10,0.26] 1.23 [1.11,1.36]
0.23 0.14 [0.06,0.23] 2.76 [1.48,5.14]
0.87 0.27 [0.17,0.37] 1.45 [1.25,1.68]
0.84 0.41 [0.30,0.51] 1.93 [1.58,2.34]
0.11 0.07 [0.00,0.13] 2.59 [1.03,6.48]
0.06 -0.09 [-0.2,-0.02] 0.39 [0.20,0.86]
HCT (n=146) Choice arm (n=141)
Mean count of outcome Count difference
1.03 1.89 0.87 [0.7,1.02]
2.79 4.97 2.18 [1.6,2.77]
0.09 0.30 0.22 [0.1,0.33]
1.32 2.96 1.64 [1.2,2.07]
* 1.32 2.91 1.59 [1.2,2.02]
0.78 2.76 1.98 [1.6,2.36]
he index participant. * Data are from peer/partners
Fig. 2. CONSORT Diagram: Peer/partner participants.
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had at least one peer/partner report testing for HIV vs. 44% for the
HCT arm (RR 1.93, 95% CI 1.58,2.34) (Table 2). This is not only due to
simply inviting more peers and partners; peers and partners who
were invited by choice arm index cases were individually more likely
to enroll in the trial (RR 1.26, 95% CI 1.08,1.48). Overall by 9-months,
of those peers and partners who came in for a study visit, 93% of
choice arm peer/partners reported having tested compared to 59%
peer/partners in the HCT arm (RR 1.58, 95% CI 1.37-1.85) (Table 3).
3.1.2. Experiences with HIV self-testing
Among the index HIVST users, when asked what they did after
getting their test result at the 3-month visit, of those that reportedtesting positive (n=4) most reported calling a friend or relative, talk-
ing to a friend or relative, or getting a confirmatory test. Of those
who tested negative, most (n=66) reported doing nothing/ not talking
to anyone and 23 said they talked to a friend, family member or part-
ner. Thirty-three percent (41/125) reported needing someone to talk
to during the HIVST however only 6 reported calling the toll-free
study number provided most (n=63) reported not calling the num-
ber because they did not want to talk to the study counselor. Ninety-
percent (113/125) reported feeling they received the support they
needed to use the HIVST. Of these, friends and family (n=40), the
online video (n=28) and partners (n=23) were reported to be the
most helpful sources of support. Eighty-one percent of women who
received HIV self-test kits reported talking to a partner about HIV
Table 3
Differences in characteristics of peers / partners between invited by index participants from each arm by month 3.
Panel a: All peers/partners invited by index participant by month 3 HCT (n=198) Choice arm (n=373)
Binary outcome variables Proportion of outcome Risk difference Risk ratio
Male* 0.19 0.26 0.08 [0.01,0.16] 1.43 [1.03,2.10]
Sexual partner* 0.04 0.08 0.04 [-0.00,0.07] 1.77 [0.93,4.44]
Came in for a study visit 0.55 0.64 0.09 [-0.00,0.19] 1.17 [1.00,1.40]
Used at least one kit/card from index 0.15 0.32 0.29 [0.19,0.38] 1.90 [1.52,2.48]
Had at least one positive test result 0.01 0.01 -0.00 [-0.03,0.03] 0.96 [0.32,4.67]
Mean/count outcome variables Mean of outcome Mean/count differences
Age* 23.9 24.0 0.35 [-2.00,2.33]
Panel b: Peers/partners who came in for a clinic visit for study HCT (n=108) Choice arm (n=238)
Binary outcome variables Proportion of outcome Risk difference Risk ratio
Male 0.19 0.29 0.10 [0.00,0.20] 1.54 [1.00,2.64]
Sexual partner* 0.06 0.08 0.02 [-0.03,0.08] 1.44 [0.66,4.80]
Ever previously tested 0.83 0.87 0.04 [-0.05,0.12] 1.04 [0.95,1.16]
Used at least one kit/card from index 0.58 0.95 0.36 [0.24,0.48] 1.62 [1.35,2.01]
Had at least one positive test result 0.05 0.04 -0.01 [-0.06,0.04] 0.82 [0.27,3.58]
Mean/count outcome variables Mean of outcome Mean/count differences
Age 24.9 23.9 -1.08 [-3.56,1.40]
Years of school 11.9 12.1 0.24 [-0.07,0.55]
Panel c: All peers/partners invited by index participant by month 9 HCT (n=406) Choice arm (n=701)
Binary outcome variables Proportion of outcome Risk difference Risk ratio
Male* 0.19 0.26 0.07 [0.02,0.12] 1.38 [1.03,1.90]
Sexual partner* 0.04 0.08 0.04 [0.01,0.07] 1.93 [1.12,3.79]
Came in for a study visit 0.47 0.60 0.12 [0.06,0.18] 1.26 [1.08,1.42]
Used at least one kit/card from index 0.28 0.56 0.28 [0.22,0.33] 1.98 [1.62,2.49]
Had at least one positive test result 0.02 0.02 0.01 [-0.01,0.02] 1.41 [0.58,5.31]
Mean/count outcome variables Mean of outcome Mean/count differences
Age* 23.9 24.0 0.12 [-1.00,1.20]
Panel d: Peers/partners who came in for a clinic visit for study HCT (n=193) Choice arm (n=417)
Binary outcome variables Proportion of outcome Risk difference Risk ratio
Male 0.17 0.26 0.09 [0.02,0.16] 1.51 [1.04,2.31]
Sexual partner* 0.05 0.07 0.02 [-0.02,0.07] 1.43 [0.72,3.66]
Ever previously tested 0.85 0.89 0.04 [-0.02,0.10] 1.05 [0.97,1.13]
Used at least one kit/card from index 0.59 0.93 0.34 [0.28,0.40] 1.58 [1.37,1.85]
Had at least one positive test result 0.04 0.04 0.00 [-0.03,0.04] 1.12 [0.46,4.22]
Mean/count outcome variables Mean of outcome Mean/count differences
Age (indicated by PP) 25.4 24.5 -0.86 [-2.32,0.60]
Years of school 11.9 12.1 0.18 [-0.03,0.40]
Unless otherwise noted, all data are self-reported from the peer/partner. * Data are indicated by the index participant.
8 A. Pettifor et al. / EClinicalMedicine 21 (2020) 100327testing at the 3 month visit and 36% reported that they offered the kit
to someone who refused to use it.
When asked about the circumstances around taking the test, the
majority (94% (n=117/125) reported conducting the test at their
home or where they live; only 6 reported testing at their sex part-
ner’s house. Most reported testing alone (55%, n=69/125), 16 (13%)
with a partner, 15 (12%) with a sister, 8 (6%) reported a friend, 6 (5%)
their mother, and 5 (5%) another relative. Of those testing with some-
one present (43%, n=54/125), the majority reported it made testing
easier (89%, 48/54). Of these, the main reasons they reported it being
easier were because they felt safer and less scared with someone
present (n=17) and the person supported them during the test (n=15)
Four percent (n=12/287) of index participants reported testing
positive during the trial, 5 in the HCT arm and 7 in the choice arm,
yielding little power to detect risk differences of testing positive ever
between the two groups (RD=-0.01, 95% CI -0.05,0.04). Of the 7 indi-
viduals reporting testing positive in the choice arm, 4 reported going
to the clinic for confirmatory testing. At the 9-month visit, all index
participants who reported being HIV negative were offered an
observed oral self-test, 14 tested positive (12/14 were HIV ELISA posi-
tive at 9 months and 10/14 were HIV ELISA positive at baseline
there were two confirmed seroconversions during the study and
two false positives). Six refused the observed oral self-test (3 ofwhom tested HIV ELISA positive at baseline and 9 months). Of the 9
individuals who reported being HIV positive at 3 or 9 months, all 9
tested HIV ELISA positive at baseline. The 14 who tested positive at 9
months on the observed self-test were evenly distributed by study
arm. Interestingly, only 2/7 reported testing during the study in the
HCT arm (both reported being negative) while 6/7 repored testing
using the self-test kit but 5/6 reported being negative.
4. Discussion
In this randomized trial where young women in rural South Africa
were randomized to either HCT or to a choice of using an HIV self-
test or going for clinic based HCT. We found that providing partici-
pants with a choice of testing modality resulted in significantly more
testing events at the follow-up visits with the vast majority (96%) of
the choice arm choosing self-testing. At 3-months 92% of young
women in the choice/self-test arm compared to 43% in the HCT arm
tested for HIV resulting in a risk difference of 49%. We also found that
participants in the choice arm were significantly more likely to give
test kits/invitations to peers and partners compared to the HCT arm
and that those peers and partners were more likely to report testing
for HIV. The large difference in testing uptake among the choice/self-
test group provides more compelling evidence that providing HIVST
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among those receiving self-test kits but also through secondary dis-
tribution to friends, family and partners.
HIV self-testing makes HIV testing more accessible to individuals
by reducing barriers that are often cited by individuals as reasons for
not testing, including access to clinics (distance, opening hours, wait-
ing times) and confidentiality and privacy [9,10]. While recent
national surveys suggest that countries in sub-Saharan Africa (SSA)
are making great strides towards reaching the UNAIDS goal of 90% of
individuals testing and knowing their status, it has also become
apparent that younger people are less likely to have tested than other
populations [23]. HIVST is becoming more widely available in many
countries in SSA with a number of large demonstration studies
underway [24], and a growing number of randomized trials and
observational studies have shown that offering HIVST can increase
the uptake and frequency of testing although these have been con-
ducted to date among pregnant and post-partum women, female sex
workers, truck drivers and MSM rather than the general population
[7,25].
We found young women strongly prefered self-testing to HCT: in
our choice arm 95% of young women chose the HIVST over the option
of attending the clinic. We chose this study design as it simulates the
choice individuals might have in the real world if HIVST become
available through community distribution, clinics, pharmacies or
other means (free of charge). In this study HIVST was the clear favor-
ite over clinic-based testing. While the vast majority of participants
in this study reported having tested before and tested in the last 12
months, access to HIVST significantly increased testing rates in this
group of young women and among their peers and partners. The later
findings being particularly significant for men, who were more likely
to uptake HIVST as compared to HCT and who have fewer reasons to
attend clinics and thus be exposed to HCT. Women who are pregnant,
have small children or seeking contraception are likely to attend
clinic regularly and thus have greater to access to HIV testing there-
fore HIVST programs need to focus identifying non-clinic attending
young women. It is notable that the difference between the HIVST
and HCT arm decreased over time; the largest difference in testing
was in the first 3 months highlighting that young people, especially
young women, may test at clinics when they access other services
over the year. HIVST fills a particular gap for those individuals who
do not attend clinics regularly or who are worried about recent expo-
sure to the virus; with the rollout of Pre Exposure Prophylaxis (PrEP)
the need for more rapid and on demand testing may increase and
HIVST may help fill this important gap.
Distribution of HIVST and HCT invitations to male partners in this
population was less than we had hoped but by 9 months 23% of
women in the choice/self test arm had given an HIVST kit to a male
partner compared to 8% giving an invitation to test in the HCT arm.
Other studies of HIVST distribution to partners have found much
higher levels of distribution to partners; however, these populations
have been among pregnant women (ages 18-39), female sex workers
(FSW) and men who have sex with men (MSM) [13,14,15]. In Kenya,
91% of women attending ANC who had a primary partner distributed
kits to their partner, and 75% of FSWs distributed to commercial sex
clients [15]. In a similar study in Kisumu, the same authors found
that 91% of women (again ANC and FSW) reported partner HIV test-
ing in the HIVST group compared to women who invited partners to
come to the clinic to test [14]. In a study among MSM in South Africa,
65% gave a test kit to a partner [13]. Differences in distribution rates
to partners in our study may be because these are younger women
(18-26 years) who were not married or cohabiting with partners and
thus may not have been as comfortable providing kits to their part-
ners. Interestingly, 81% of young women who used the HIVST
reported talking to their partner about HIV testing after using the
HIVST so it is possible testing might encourage male partners to test
down the line. Given that this population is one of the highest risk interms of HIV incidence, it is encouraging that these young women
were willing to test and distribute kits to their female friends and
family; however given somewhat limited distribution to partners,
finding other strategies to reach men with HIV testing, such as direct
distribution of self-tests to men in places where they gather and tak-
ing testing services to men, is essential.
We did not have any reports of adverse events as a result of sec-
ondary distribution of kits to peers and partners. That said, we did
advise women not to provide kits to partners where there was a his-
tory of violence or if they worried providing a kit might insite vio-
lence. Interestingly, 36% of young women reported that they offered
the HIVST kit to someone who refused it, so it is possible that male
partners were offered kits and refused to use them.
A key rationale for HIVST is to reach those who do not test regu-
larly and do not want or are unable to attend routine testing services.
At the 9-month visit, 9 individuals self-reported having tested posi-
tive for HIV during the study and another 12 individuals tested posi-
tive on the DBS. The majority of those testing positive in the self-test
arm did report having tested during the study while few individuals
in the HCT arm reported testing. It is most likely those who tested
were not comfortable reporting that they were HIV positive to the
interviewer given the majority were positive at baseline based on
DBS results.
Limitations of the study include the fact that testing uptake are
based on self-report. We did try to collect the invitations for HCT
from the clinics (we provided boxes for the counselors to put invita-
tions in and all invitations were linked with a unique ID number) but
very few individuals returned these invitations to clinics. It is cer-
tainly possible that individuals overreported testing, however, there
is no reason to believe reporting between arms would be differential.
In addition, the self-report of prior HIV testing was very high among
index cases and peer/partners thus results may be different in a pop-
ulation with less testing experience. Strengths of this study include
that it was randomized, removing potential selection bias from those
that might opt to enroll in a self-test study (perhaps they are more
likely to test than those not choosing to be in a study). In addition,
we followed up with peers and partners who were provided test kits/
invitations to determine their experiences with the test.
Given a choice, young women significantly preferred self-testing
to clinic testing, and having chosen self-testing, they tested at much
higher rates and provided test kits to more of their peers and partners
than those being offered standard clinic-based HCT. Future research
should pursue the best ways to reach young men and those not in
stable partnerships with HIVST and other novel testing approaches
that reduce wait times and increase confidentiality. While those that
test positive must still attend clinics for confirmatory testing and to
access treatment, allowing individuals to test at their convenience
and on their own terms can be empowering for young people and
will reach more populations in need of routine HIV testing.
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